Vaxart (VXRT) AI Stock Analysis

Vaxart

(BMV:VXRT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Oral vaccine platformThe proprietary oral delivery approach could differentiate Vaxart from injectable competitors through easier administration, storage, and broader deployment potential. Its applicability across COVID, norovirus, influenza, HPV, and HBV also creates a platform opportunity beyond any single vaccine program.

Negative Factors

Declining and volatile revenueFalling revenue weakens confidence that current profitability and cash generation can persist, particularly because the business has historically shown highly volatile revenue and margins. Continued contraction could reduce internal funding capacity and increase dependence on BARDA, partners, or external capital.

Vaxart (VXRT) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 101.99M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 2.9
Beta (1Y): 0.17
Revenue Growth: ―
EPS Growth: ―
Country: Mexico
Employees: 65
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Vaxart Business Overview & Revenue Model

Company Description

Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for deliv...

Vaxart Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:0.00%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNeutral

The call presents a balanced mix of encouraging clinical and operational developments alongside material financial and timing risks. Key positives include a clean 12‑month safety signal in the sentinel cohort, BARDA’s $29 million contract modification enabling deeper analyses, a fully enrolled ~5,000‑participant main cohort with topline expected H1 2027, governance improvements, and a defined cash runway with flexible financing options. Offsetting these are a ~31.5% year‑over‑year revenue decline, a limited cash runway into Q2 2027 that creates timing pressure for funding or partner opt‑ins, reliance on BARDA for data release timing, uncertainty around the norovirus partnership and development timelines, and that the sentinel cohort was not powered to demonstrate efficacy (symptomatic case counts were similar between arms). On balance, positives (safety readout, BARDA support, large main cohort enrollment, governance actions) are meaningful but are matched by significant near‑term financing and commercialization uncertainties; the overall tone is constructive but cautious.

Positive Updates

Positive 12-Month Safety Readout from Phase IIb Sentinel Cohort

In July Vaxart reported positive 12-month safety data from the ~400‑participant sentinel cohort in the Phase IIb COVID-19 trial: 0 vaccine‑related serious health complications and 0 severe or long‑lasting adverse events in either the oral pill or mRNA comparator arms.

Negative Updates

Significant Revenue Decline Year‑over‑Year

Revenue for Q2 2026 was $27.2 million vs $39.7 million in Q2 2025, a decline of $12.5 million (approximately a 31.5% decrease), with revenue primarily from BARDA and $2.9 million from a Dynavax license and collaboration.

Company Guidance

Management reiterated that top-line efficacy and safety from the Phase IIb main cohort of ~5,000 participants is expected in H1 2027, following positive 12‑month safety data from the 400‑participant sentinel cohort (201 oral pill, 199 mRNA) that showed 0 vaccine‑related serious adverse events, symptomatic COVID in 33 pill vs 30 mRNA recipients and 12 asymptomatic cases in each arm; reported side‑effect rates for the pill were ~20.9% fatigue, 18.9% headache and ~10% loss of appetite versus >60% injection‑site pain, 40.2% tenderness, 35.2% fatigue, 33.2% muscle pain and 28.6% headache for the mRNA comparator. Financially, Vaxart ended Q2 2026 with $64.0M cash and a cash runway into Q2 2027, Q2 revenue was $27.2M (vs $39.7M YoY), R&D expense $33.7M (vs $49.7M), G&A $6.6M, and net loss $13.5M or $0.06/share (vs $15.0M or $0.07/share prior year); management also cited a $29M BARDA contract modification to fund expanded mucosal, genomic and cellular analyses across the 5,000+ cohort, an available $25M Lincoln Park equity facility, and that BARDA controls timing/content of data releases.

Vaxart Risk Analysis

Vaxart disclosed 93 risk factors in its most recent earnings report. Vaxart reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Our common stock has been delisted from The Nasdaq Capital Market. There can therefore be no assurance that it will trade on a national exchange again.Q2, 2026

2.We may not be able to retain coverage by securities or industry analysts because our common stock is not traded on a national securities exchange.Q2, 2026

3.There can be no assurance that Dynavax Technologies Corporation, a Sanofi company ("Dynavax") will continue to perform the obligations under the 2025 License and Collaboration Agreement or that Dynavax will not exercise its right to terminate the agreement.Q2, 2026

Vaxart Peers Comparison

Overall Rating

Financial Indicators

MX:VXRT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:VXRT and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	MX:VXRT	Vaxart	12.00	0.00	0.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Vaxart AI Stock Analysis